

Directions



Traveling south on Freeway 99 (from Northern California)

Once you arrive in the Fresno area, take Herndon exit. Turn left onto Herndon Avenue. Stay on Herndon to Millbrook Ave. (approximately 9 miles). Turn right onto Frontage Road.

Traveling north on Freeway 99 to Highway 41 (from Southern California)

Once you arrive in the Fresno area, take Herndon exit. Turn right onto Herndon Avenue to Millbrook Ave. (approximately 1 mile). Turn right onto Frontage Road.

Register

Saint Agnes Medical Center Staff, Nurses and Allied Health Professionals – **No charge**
VA Hospital Physicians, Nurses and Affiliated Healthcare Staff – **No charge**
Non-Saint Agnes Physicians – **No charge** • Nurses/Others – **No charge**

Preregistration is required. Please register online at www.samc.com. Registration must be received by March 4, 2011, to be guaranteed a participant syllabus. If you have questions or problems registering online, send an e-mail to medicaleducation@samc.com or call (559) 450-7566.

Registration at the door is dependent on space availability.

5 AMA PRA Category 1 Credits™ to be awarded

Non-Profit Org.
U.S. Postage
PAID
Fresno, CA
Permit No. 280



**Saint Agnes
Medical Center**
1303 E. Herndon Ave.
Fresno, CA 93720

ADDRESS SERVICE REQUESTED


3rd Annual

Central
California
Cardiometabolic
Risk
Symposium

Focus on
Women



California
Cardiovascular
Institute



3rd Annual

Central California Cardiometabolic Risk Symposium

Focus on Women

Saturday, March 19, 2011

7:30 a.m.-2:30 p.m.

Saint Agnes Medical Center

Shehadey Pavilion

1303 E. Herndon Ave., Fresno, Calif.

Attend the **most comprehensive cardiometabolic risk management event in the Central Valley!**

Presented by:

Saint Agnes Medical Center

Medical Education Program

California Cardiovascular Institute

John R. Nelson, MD, FACC, Program Director

Teaching Objectives

- **Describe** specific lifestyle behaviors that substantially reduce cardiovascular event risk.
- **Interpret** clinical trial evidence that supports treatment of dyslipidemia in women to prevent cardiovascular disease (CVD) and apply the data in their treatment.
- **Synthesize** data for use of statins for the secondary prevention of CVD in women.
- **Discuss** recent data from “Jupiter” trial and updated meta-analysis addressing use of statins for the primary prevention of CVD in women.
- **Explain** long-term implications of dyslipidemia in pregnancy.

Target Audience

Primary care physicians, endocrinologists, obesity specialists, nurse practitioners, nurses, pharmacists, and other healthcare professionals who are interested in the treatment of patients with cardiometabolic risk factors and related cardiometabolic complications.

Program Moderator

John R. Nelson, MD, FACC

Director, California Cardiovascular Institute; President-Elect, Pacific Lipid Association; Assistant Clinical Professor, UCSF School of Medicine; Fresno Medical Residency Program – Volunteer; Symposium Program Director, Fresno, Calif.

7:30 a.m. • Registration / Breakfast / Exhibits

8:00 • Welcome / Introduction

J. W. Randolph Bolton, MD, CME Chair

Saint Agnes Medical Education Program, Fresno, Calif.

8:15

Treating Dyslipidemia to Prevent Cardiovascular Disease in Women: What is the Evidence?

Vera Bittner, MD, MSPH

Professor of Medicine, Section Head, Preventive Cardiology, University of Alabama at Birmingham, Division of Cardiovascular Disease, Birmingham, Ala.

8:55

Beyond Clinical Risk Factors: Genomic to Metabolomic Profiling Clinical Implications

Robert J. Chilton, DO

Professor of Medicine and Director of Cardiac Catheterization Laboratories, University of Texas Health Science Center, San Antonio, Texas

9:35 • Break / Vendors

9:55 • Keynote Speaker

Treatment of TZDM: A Sound Approach Based Upon Its Pathophysiology

Ralph A. DeFronzo, MD

Professor of Medicine and Chief, Diabetes Division, University of Texas Health Science Center and Audie L. Murphy Memorial VA Hospital, San Antonio, Texas

10:35

Pregnancy and Dyslipidemia

Robert A. Wild, MD, PhD, MPH

Professor of Preventive Cardiology and Women's Health and Professor of Epidemiology, Oklahoma University Health Sciences Center, Oklahoma City, Okla.

11:15 • Panel Discussion / Q & A

11:45 • Lunch / Exhibits

12:30 p.m.

Identification and Management of High Risk; Primary Prevention of Dyslipidemic Patients

Thomas P. Bersot, MD, PhD

Associate Investigator, Gladstone Institutes; Professor of Medicine, UCSF, San Francisco, Calif.

1:10

Statins for Primary Prevention of Cardiovascular Disease in Women

Samia Mora, MD, MHS

Associate Physician, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Mass.

1:50 • Q & A

2:30 • Adjournment

Accreditation Statement

Saint Agnes Medical Center is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. Saint Agnes Medical Center takes responsibility for the content, quality and scientific integrity of this CME activity. Saint Agnes Medical Center designates this educational activity for a maximum of **5 AMA PRA Category 1 Credits**.™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit also may be applied to the CMA Certification in Continuing Medical Education. Each physician should only claim those hours of credit that he or she actually spent in the educational activity.

Saint Agnes Medical Center is approved by the California Board of Registered Nursing as a provider of continuing education under Provider No. 00262. **5.0 CE contact hours** are approved for this course.

NLA Statement

The National Lipid Association is recognized to endorse the credit hours offered by this activity as “lipid-focused” continuing medical education that meets the credentialing and certification standards established by the American Board of Clinical Lipidology (www.lipidboard.org) and the Accreditation Council for Clinical Lipidology (www.lipidspecialist.org)

